WHO guidelines. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Who. 2018.
Ly K, Hughes E, Jiles R, Holmberg S. Rising mortality associated with hepatitis C virus in the United States, 2003–2013. Clin Inf Dis. 2016;62(10):1287–8.
Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. :2012.
Smith BD, Jorgensen C, Zibbell JE, Beckett GA. Centers for Disease Control and Prevention initiatives to prevent hepatitis C virus infection: a selective update. Clin Infect Dis. 2012;55:S49–52.
Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825–32.
Pradat P, Voirin N, Tillmann HL, Chevallier M, Trépo C. Progression to cirrhosis in hepatitis C patients: an age-dependent process. Liver Int. 2007;27(3):335–9.
Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: A cross sectional and longitudinal study. Gut. 2003;52(4):574–9.
Castrejon M, Chew K, Javanbakht M, Humphries R, Saab S. Implementation of a large system-wide hepatitis C virus screening and linkage to care program for baby boomers. Open Forum Infectious Dis. 2017;4(3):1–6.
Vespasiani-Gentilucci U, Galati G, Gallo P, De Vincentis A, Riva E, Picardi A. Hepatitis C treatment in the elderly: new possibilities and controversies towards interferon-free regimens. World J Gastroenterol. 2015;21(24):7412–26.
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–98.
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93.
Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari Z. Ben, Zhao Y, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163(1):1–13.
Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. J Hepatol. 2017;67(2):263–71.
Feld JJ, Jacobson IM, Hode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for hcv genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.
Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, et al. The changing epidemiology of hepatitis C virus infection in the United States: National health and nutrition examination survey, through 2010. J Hepatol. 2014;60(40):691–8.
Arora S, Thornton K, Murata G, Deming P, et al. OUtcomes of treatment for hepatitis c virus infection by providers. N Engl J Med. 2011;364:2199–207.
Fleming B, Ifeachor A, Andres A, Reese L, et al. Improving veteran access to treatment for hepatitis C virus infection. Fed Pract. 2017;34(4):S24–8.
Diseases L, Society ID, Present A, Updated L. AASLD/IDSA HCV guidance: recommendations for testing, managing, and treating hepatitis C. Clin Liver Dis. 2018;12(5):117.
Marcus EL, Tur-Kaspa R. Viral hepatitis in older adults. J Am Geriatr Soc. 1997;45:755–63.
Reid M, Price JC, Tien PC. Hepatitis C virus infection in the older patient. Infect Dis Clin North Am. 2017;31(4):827–38.
Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis. 2000; 20(1).
Younossi Z, Gordon S, Ahmen A, Dieterich D, Saab S, Beckerman R. Treating Medicaid patients with hepatitis C: clinical and economic impact. Am J Manag Care. 2017;23(2):107–12.
Chong CAKY, Gulamhussein A, Jenny Heathcote E, Lilly L, Sherman M, Naglie G, et al. Health state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98(3):630–8.
Vespasiani-Gentilucci U, Gallo P, De Vincentis A, Galati G, Picardi A. Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis. World J Gastroenterol. 2014;20(11):2825–38.
Hassoun Z, Willems B, Deslauriers J, Nguyen BN, Huet PM. Assessment of fatigue in patients with chronic hepatitis C using the fatigue impact scale. Dig Dis Sci. 2002;47(12):2674–81.
Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology. 2007;50(1):16–23.
Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, et al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology. 2016;63(4):1112–9.
Foster GR, Asselah T, Kopecky-Bromberg S, Lei Y, Asatryan A, Trinh R, et al. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One. 2019;14(1):1–13.
Shiffman ML, Sulkowski MS, Foster GR, Byrne S, Wolf J, Grabowski C, et al. Safety and efficacy of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C in patients aged 65 years or older: a retrospective analysis of phase 3 studies. Gastroenterology. 2017;152(5):S1097.
Flamm S, Peng C-Y, Shibolet O, Nahass R, Hwang P, Barr E, et al. Efficacy and safety of elbasvir/grazoprevir in hepatitis C virus GT1- and GT4-infected people aged 65 years or older. Gerontol Geriatr Med. 2019;5:1–10.
•• Su F, Beste LA, Green PK, Berry K, Ioannou GN. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: A real-world study of 17,487 patients. Eur J Gastroenterol Hepatol. 2017;29(6):686–93 DAAs produce high rates of SVR in all age groups, including patients in our oldest age category (≥75 years).
•• Lens S, Fernández I, Rodríguez-Tajes S, Hontangas V, Vergara M, Forné M, et al. Interferon-free therapy in elderly patients with advanced liver diseas. Am J Gastroenterol. 2017;112(9):1400–9 SVR rates with interferon-free regimens in elderly patients are high and comparable to the general population.
• Conti F, Brillanti S, Buonfiglioli F, Vukotic R, Morelli MC, Lalanne C, et al. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat. 2017;24(6):454–63 SVR12 rates were similar between age groups (90.5% in < 65 years vs. 94.7% in ≥ 65 years, P = 0.074).
Mücke MM, Herrmann E, Mücke VT, Graf C, Zeuzem S, Vermehren J. Efficacy and safety of direct-acting antivirals for hepatitis C in the elderly: a systematic review and meta-analysis. Liver Int. 2019;39(9):1652–60.
Villani R, Monami M, Di Cosimo F, Fioravanti G, Mannucci E, Vendemiale G, et al. Direct-acting antivirals for HCV treatment in older patients: a systematic review and meta-analysis. J Viral Hepat. 2019;39(9):1652–60.
Vermehren J, Peiffer KH, Welsch C, Grammatikos G, Welker MW, Weiler N, et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44:856–65.
Dienstag JL, Goldin RD, Heathcote EJ, Hann HWL, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124(1):105–17.
D’Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56:532–43.
Parker BM, Wu J, You J, Barnes DS, Yerian L, Kirwan JP, et al. Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery. BMC Obes. 2017;4(32):1–9.
Facciorusso A, Del Prete V, Turco A, Buccino RV, Nacchiero MC, Muscatiello N. Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: Results from a 5-year cohort study. J Gastroenterol Hepatol. 2018;33(4):942–9.
Terrault NA. Care of patients following cure of hepatitis C virus infection. Gastroenterol Hepatol. 2018;14:629–34.
Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology. 2018;155:411–21.
Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2018;155(2):411–21.
Kobayashi S, Takeda T, Enomoto M, Tamori A, Kawada N, Habu D, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int. 2007;27(2):186–91.
Papic N, Budimir J, Kurelac I, Dušek D, Jugović D, Krajcar N, et al. Treatment of elderly patients with chronic hepatitis C: a retrospective cohort study. Acta Clin Croat. 2018;57:61–70.